Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Quality of life
[44] Systematic review	1529 people 5 RCTs in this analysis	Fatigue component of the Chronic Respiratory Disease Questionnaire (CRQ) 85 days with ipratropium plus short-acting beta2 agonist with short-acting beta2 agonist alone Absolute results not reported	WMD +0.01 95% CI –0.10 to +0.13 P = 0.8		Not significant
[44] Systematic review	1529 people 5 RCTs in this analysis	Emotion component of the CRQ 85 days with ipratropium plus short-acting beta2 agonist with short-acting beta2 agonist alone Absolute results not reported	WMD +0.02 95% CI –0.12 to +0.16 P = 0.8		Not significant
[44] Systematic review	1529 people 5 RCTs in this analysis	Mastery component of the CRQ 85 days with ipratropium plus short-acting beta2 agonist with short-acting beta2 agonist alone Absolute results not reported	WMD +0.03 95% CI –0.09 to +0.15 P = 0.6		Not significant